Ametropia and presbyopia successfully treated with diffractive bifocal IOL

Article

Bilateral implantation of the Acri.LISA 366D diffractive bifocal IOL is effective in ametropic and presbyopic eyes, according to findings published in the European Journal of Ophthalmology

Bilateral implantation of the Acri.LISA 366D diffractive bifocal IOL is effective in ametropic and presbyopic eyes, according to findings published in the European Journal of Ophthalmology.

A team led by Dr José F. Alfonso, Instituto Oftalmológico Fernández-Vega, Oviedo, Spain, studied 66 eyes in 33 consecutive patients. They were examined after refractive lens exchange (RLE) and implanted with the IOL. Eyes were split into myopic and hyperopic groups. The patient's monocular uncorrected distance visual acuity, best-corrected distance visual acuity (BCVA), uncorrected distance near visual acuity, and best distance-corrected near visual acuity (BCNVA) were measured preoperatively and at 6 months post-op.

The results showed that in the myopic group 2 eyes lost one line, 4 eyes gained 1 line and 6 eyes gained 2 lines. The hyperopic group 11 eyes lost 1 line, 8 eyes gained 1 line and 7 eyes gained 2 lines.

It was concluded that the use of Acri.LISA 366DD after RLE is an effective procedure for the treatment of presbyopia and ametropia.

Related Videos
A screenshot of Dr Filomena Ribeiro, president of the ESCRS
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.